vs
Side-by-side financial comparison of MGIC INVESTMENT CORP (MTG) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $297.1M, roughly 1.0× MGIC INVESTMENT CORP). MGIC INVESTMENT CORP runs the higher net margin — 55.6% vs 16.4%, a 39.3% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -3.0%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -1.4%).
MGIC Investment Corporation NYSE: MTG ("MGIC") is a provider of private mortgage insurance in the United States. The company is headquartered in Milwaukee, Wisconsin.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
MTG vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $297.1M | $311.4M |
| Net Profit | $165.3M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 55.6% | 16.4% |
| Revenue YoY | -3.0% | -1.5% |
| Net Profit YoY | -10.9% | 126.0% |
| EPS (diluted) | $0.76 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $297.1M | $311.4M | ||
| Q4 25 | $298.7M | $295.9M | ||
| Q3 25 | $304.5M | — | ||
| Q2 25 | $304.2M | $317.0M | ||
| Q1 25 | $306.2M | $316.2M | ||
| Q4 24 | $301.4M | $297.0M | ||
| Q3 24 | $306.6M | $289.5M | ||
| Q2 24 | $305.3M | $306.1M |
| Q1 26 | $165.3M | $51.0M | ||
| Q4 25 | $169.3M | $38.0M | ||
| Q3 25 | $191.1M | — | ||
| Q2 25 | $192.5M | $-17.7M | ||
| Q1 25 | $185.5M | $22.6M | ||
| Q4 24 | $184.7M | $34.9M | ||
| Q3 24 | $200.0M | $33.6M | ||
| Q2 24 | $204.2M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 71.2% | 18.4% | ||
| Q3 25 | 77.2% | — | ||
| Q2 25 | 80.9% | -7.5% | ||
| Q1 25 | 76.6% | 12.2% | ||
| Q4 24 | 77.9% | 16.0% | ||
| Q3 24 | 82.9% | 13.8% | ||
| Q2 24 | 85.1% | 15.0% |
| Q1 26 | 55.6% | 16.4% | ||
| Q4 25 | 56.7% | 12.8% | ||
| Q3 25 | 62.8% | — | ||
| Q2 25 | 63.3% | -5.6% | ||
| Q1 25 | 60.6% | 7.1% | ||
| Q4 24 | 61.3% | 11.7% | ||
| Q3 24 | 65.2% | 11.6% | ||
| Q2 24 | 66.9% | 13.3% |
| Q1 26 | $0.76 | $0.32 | ||
| Q4 25 | $0.75 | $0.24 | ||
| Q3 25 | $0.83 | — | ||
| Q2 25 | $0.81 | $-0.11 | ||
| Q1 25 | $0.75 | $0.14 | ||
| Q4 24 | $0.71 | $0.22 | ||
| Q3 24 | $0.77 | $0.21 | ||
| Q2 24 | $0.77 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $235.1M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.0B | $2.1B |
| Total Assets | $6.4B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $235.1M | $209.8M | ||
| Q4 25 | $369.0M | $172.9M | ||
| Q3 25 | $266.9M | — | ||
| Q2 25 | $294.9M | $162.2M | ||
| Q1 25 | $207.0M | $140.7M | ||
| Q4 24 | $229.5M | $177.5M | ||
| Q3 24 | $288.6M | $187.5M | ||
| Q2 24 | $281.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $5.0B | $2.1B | ||
| Q4 25 | $5.1B | $2.0B | ||
| Q3 25 | $5.2B | — | ||
| Q2 25 | $5.2B | $1.9B | ||
| Q1 25 | $5.1B | $2.0B | ||
| Q4 24 | $5.2B | $2.1B | ||
| Q3 24 | $5.3B | $2.1B | ||
| Q2 24 | $5.1B | $2.1B |
| Q1 26 | $6.4B | $2.6B | ||
| Q4 25 | $6.6B | $2.5B | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $6.5B | $2.6B | ||
| Q1 25 | $6.5B | $2.6B | ||
| Q4 24 | $6.5B | $2.7B | ||
| Q3 24 | $6.7B | $2.7B | ||
| Q2 24 | $6.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MTG
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
